Data from Incyte’s Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

Rhea-AI Summary

Incyte (Nasdaq:INCY) announced its participation in the Society for Immunotherapy of Cancer’s 36th Annual Meeting from November 10-14, 2021. Key presentations include a late-breaking poster on Retifanlimab for recurrent MSI-H/dMMR endometrial cancer and a Phase 1 study on an oral PD-L1 inhibitor for advanced solid tumors. An investor conference call will occur on November 13, 2021, discussing oral PD-L1 clinical developments. Full abstracts will be available on SITC’s website starting November 9, 2021.

Positive

• Presentation of late-breaking data on Retifanlimab indicates strong clinical interest.
• Incyte's commitment to addressing unmet medical needs in oncology highlighted through multiple presentations.

Negative

• None.

Investor conference call and webcast scheduled for November 13, 2021, at 6:30 p.m. ET

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced that multiple abstracts highlighting data from its oncology portfolio will be presented at the Society for Immunotherapy of Cancer’s (SITC) 36^th Annual Meeting, held from November 10-14, 2021 in Washington, D.C and virtually.

“We look forward to presenting data from multiple programs within Incyte’s immuno-oncology portfolio at this year’s SITC conference,” said Lance Leopold, M.D., Group Vice President, Immuno-Oncology, Incyte. “Data being presented from the retifanlimab POD1UM clinical program, including a late-breaking poster presentation highlighting results from the POD1UM-101 study; as well as results from a Phase 1 study evaluating an oral PD-L1 inhibitor in immune-checkpoint naïve patients with advanced solid tumors, demonstrate our commitment to addressing the needs of patients with historically difficult-to-treat cancers.”

Key abstracts include:

Late-Breaking Poster Presentation

Retifanlimab (INCMGA00012) in patients with recurrent MSI-H or dMMR endometrial cancer: Results from the POD1UM-101 Study (Abstract #956. Saturday, November 13, 7:00 a.m. – 8:30 p.m. ET)

Oral Presentation

Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors (Abstract #529. Session: Concurrent Rapid Oral Abstract Presentation: Clinical. Saturday, November 13, 12:45 – 1:45 p.m. ET)

Poster Presentation

A Phase 2 Study of Retifanlimab in Patients With Advanced or Metastatic Merkel Cell Carcinoma (MCC) (POD1UM-201) (Abstract #545. Friday, November 12, 7:00 a.m. – 8:30 p.m. ET)

Full abstracts will be available on the SITC website and in the Journal for ImmunoTherapy of Cancer (JITC) on November 9, 2021. More information regarding the conference is available on the SITC website: https://www.sitcancer.org/2021/home.

Conference Call and Webcast

Incyte will host an analyst and investor conference call and webcast on Saturday, November 13, 2021 from 6:30 – 7:30 p.m. ET to discuss its oral PD-L1 clinical development program, including data from INCB86550 which has been accepted for oral presentation at the SITC Annual Congress.

The live and archived webcast will be available via investor.incyte.com.

To access the conference call, please dial 877-407-3042 for domestic callers or +1-201-389-0864 for international callers (conference identification number 13724808). If you are unable to participate, a replay will be available for 30 days. The replay dial-in number for the United States is 877-660-6853 and the dial-in number for international callers is +1-201-612-7415 (conference identification number 13724808).

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the Company’s ongoing clinical development pipeline, its presentation plans for the upcoming SITC meeting and its goal of improving the lives of patients and finding solutions to unmet medical needs, contain predictions, estimates and other forward-looking statements.

These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; the effects of the COVID-19 pandemic and measures to address the pandemic on the Company’s clinical trials, supply chain, other third-party providers and development and discovery operations; determinations made by the U.S. FDA and other regulatory authorities outside of the United States; the efficacy or safety of the Company’s products; the acceptance of the Company’s products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its annual report and its quarterly report on Form 10-Q for the quarter ended June 30, 2021. The Company disclaims any intent or obligation to update these forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005607/en/

Media

Catalina Loveman

+1 302 498 6171

cloveman@incyte.com

Investors

Christine Chiou

+1 302 274 4773

cchiou@incyte.com

Source: Incyte

FAQ

What key presentations will Incyte showcase at the SITC Annual Meeting 2021?

Incyte will present a late-breaking poster on Retifanlimab and results from a Phase 1 study of an oral PD-L1 inhibitor.

When is Incyte's investor conference call scheduled?

The investor conference call is scheduled for November 13, 2021, at 6:30 p.m. ET.

Where can I find the abstracts presented by Incyte at the SITC conference?

Full abstracts will be available on the SITC website starting November 9, 2021.